227 related articles for article (PubMed ID: 19490562)
1. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.
Skedgel C; Rayson D; Younis T
Value Health; 2009; 12(5):641-8. PubMed ID: 19490562
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
4. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
7. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
[TBL] [Abstract][Full Text] [Related]
9. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.
Chen W; Jiang Z; Shao Z; Sun Q; Shen K
Value Health; 2009; 12 Suppl 3():S82-4. PubMed ID: 20586989
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
[TBL] [Abstract][Full Text] [Related]
11. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
Reed SD; Schulman KA
Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
[No Abstract] [Full Text] [Related]
12. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities.
Van Vlaenderen I; Canon JL; Cocquyt V; Jerusalem G; Machiels JP; Neven P; Nechelput M; Delabaye I; Gyldmark M; Annemans L
Acta Clin Belg; 2009; 64(2):100-12. PubMed ID: 19432022
[TBL] [Abstract][Full Text] [Related]
15. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
Garrison LP; Veenstra DL
Value Health; 2009; 12(8):1118-23. PubMed ID: 19624617
[TBL] [Abstract][Full Text] [Related]
16. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer.
Lidgren M; Wilking N; Jönsson B; Rehnberg C
Acta Oncol; 2008; 47(6):1018-28. PubMed ID: 18607881
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.
McKeage K; Lyseng-Williamson KA
Pharmacoeconomics; 2008; 26(8):699-719. PubMed ID: 18620462
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer.
Lidgren M; Jönsson B; Rehnberg C; Willking N; Bergh J
Ann Oncol; 2008 Mar; 19(3):487-95. PubMed ID: 18065409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]